{"url_path":"/sec/autl/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000065-index.html","accession_number":"0001730463-26-000065","cik":"0001730463","ticker":"AUTL","issuer_name":"Autolus Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000065-index.html","primary_entity_key":"0001730463","primary_entity_name":"Autolus Therapeutics plc"},"word_count":1969,"has_tables":true,"body_markdown":"autl-20260331\n0001730463false2026Q112/3100-0000000Truehttp://fasb.org/us-gaap/2025#ProductMemberhttp://fasb.org/us-gaap/2025#ProductMember11P3YP4YP2Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesiso4217:GBPxbrli:sharesautl:segmentautl:securityiso4217:GBPautl:votexbrli:pureautl:paymentautl:batchiso4217:EURautl:director00017304632026-01-012026-03-310001730463dei:AdrMember2026-01-012026-03-310001730463autl:OrdinarySharesMember2026-01-012026-03-3100017304632026-05-1300017304632026-03-3100017304632025-12-310001730463autl:OrdinarySharesMember2025-12-310001730463autl:OrdinarySharesMember2026-03-310001730463autl:DeferredSharesMember2025-12-310001730463autl:DeferredSharesMember2026-03-310001730463autl:DeferredClassBSharesMember2026-03-310001730463autl:DeferredClassBSharesMember2025-12-310001730463autl:DeferredClassCSharesMember2026-03-310001730463autl:DeferredClassCSharesMember2025-12-3100017304632025-01-012025-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2025-12-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2025-12-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2025-12-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2025-12-310001730463us-gaap:AdditionalPaidInCapitalMember2025-12-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001730463us-gaap:RetainedEarningsMember2025-12-310001730463us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001730463us-gaap:RetainedEarningsMember2026-01-012026-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2026-03-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2026-03-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2026-03-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2026-03-310001730463us-gaap:AdditionalPaidInCapitalMember2026-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001730463us-gaap:RetainedEarningsMember2026-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2024-12-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2024-12-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2024-12-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2024-12-310001730463us-gaap:AdditionalPaidInCapitalMember2024-12-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001730463us-gaap:RetainedEarningsMember2024-12-3100017304632024-12-310001730463us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2025-01-012025-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001730463us-gaap:RetainedEarningsMember2025-01-012025-03-310001730463autl:OrdinarySharesMemberus-gaap:CommonStockMember2025-03-310001730463autl:DeferredSharesMemberus-gaap:CommonStockMember2025-03-310001730463autl:DeferredClassBSharesMemberus-gaap:CommonStockMember2025-03-310001730463autl:DeferredClassCSharesMemberus-gaap:CommonStockMember2025-03-310001730463us-gaap:AdditionalPaidInCapitalMember2025-03-310001730463us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001730463us-gaap:RetainedEarningsMember2025-03-3100017304632025-03-310001730463autl:RebatesMember2025-12-310001730463autl:ChargebackMember2025-12-310001730463autl:RebatesMember2026-01-012026-03-310001730463autl:ChargebackMember2026-01-012026-03-310001730463autl:RebatesMember2026-03-310001730463autl:ChargebackMember2026-03-310001730463us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001730463us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001730463us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001730463us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001730463us-gaap:WarrantMember2026-01-012026-03-310001730463us-gaap:WarrantMember2025-01-012025-03-310001730463us-gaap:MoneyMarketFundsMember2026-03-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:CommercialPaperMember2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:CommercialPaperMember2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:CorporateDebtSecuritiesMember2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMember2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMember2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001730463us-gaap:MoneyMarketFundsMember2025-12-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMember2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMember2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:CommercialPaperMember2025-12-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:CorporateDebtSecuritiesMember2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMember2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMember2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001730463us-gaap:CommercialPaperMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:CorporateDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:USTreasuryBillSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2026-03-310001730463us-gaap:CommercialPaperMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:CorporateDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:ForeignGovernmentDebtSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:USTreasuryBillSecuritiesMemberautl:ContractualMaturityWithinOneYearMember2025-12-310001730463us-gaap:EquipmentMember2026-03-310001730463us-gaap:EquipmentMember2025-12-310001730463us-gaap:OfficeEquipmentMember2026-03-310001730463us-gaap:OfficeEquipmentMember2025-12-310001730463us-gaap:FurnitureAndFixturesMember2026-03-310001730463us-gaap:FurnitureAndFixturesMember2025-12-310001730463us-gaap:LeaseholdImprovementsMember2026-03-310001730463us-gaap:LeaseholdImprovementsMember2025-12-310001730463us-gaap:AssetUnderConstructionMember2026-03-310001730463us-gaap:AssetUnderConstructionMember2025-12-310001730463autl:UCLBusinessplcMemberus-gaap:IntellectualPropertyMember2025-07-012025-09-300001730463us-gaap:RestrictedStockUnitsRSUMember2026-03-310001730463us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2026-04-012026-05-140001730463autl:A2025EmployeeSharePurchasePlanMember2025-05-310001730463autl:A2025InducementPlanMember2025-03-270001730463autl:A2025InducementPlanMember2026-01-012026-03-310001730463autl:A2025InducementPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-01-012026-03-310001730463autl:A2025InducementPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2026-01-012026-03-310001730463autl:A2025InducementPlanMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001730463us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001730463us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001730463us-gaap:SellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001730463us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001730463us-gaap:CostOfSalesMember2026-01-012026-03-310001730463us-gaap:CostOfSalesMember2025-01-012025-03-3100017304632025-01-012025-12-310001730463us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001730463us-gaap:RestrictedStockUnitsRSUMember2025-12-310001730463us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001730463autl:BlackstoneMember2021-11-012021-11-300001730463autl:BlackstoneMember2022-12-012022-12-310001730463autl:BlackstoneMember2022-12-310001730463autl:BlackstoneMember2024-11-080001730463autl:BioNTechMemberautl:ObeCelProductMember2024-02-062024-02-060001730463autl:BioNTechMemberautl:ObeCelProductMember2024-02-060001730463autl:BioNTechMemberautl:ObeCelProductMember2024-02-012024-02-290001730463autl:BlackstoneMember2026-03-310001730463autl:BlackstoneMember2025-03-310001730463autl:BioNTechMember2026-03-310001730463autl:BioNTechMember2025-03-310001730463autl:UCLBusinessplcMember2026-01-012026-03-310001730463us-gaap:CapitalAdditionsMember2026-03-310001730463autl:ReagentsAndDisposablesMember2026-03-3100017304632026-01-212026-01-2100017304632023-01-012023-12-310001730463autl:ReportableSegmentMember2026-01-012026-03-310001730463autl:ReportableSegmentMember2025-01-012025-03-310001730463autl:BlackstoneMemberautl:AutolusMember2021-11-3000017304632021-11-300001730463autl:BlackstoneMemberautl:AutolusMember2026-03-310001730463autl:BlackstoneMember2026-01-012026-03-310001730463autl:BlackstoneMember2025-12-310001730463autl:BioNTechMemberautl:AutolusMember2026-03-310001730463autl:BioNTechMember2026-01-012026-03-310001730463autl:BioNTechMember2025-12-310001730463srt:ScenarioForecastMember2025-07-012026-09-300001730463us-gaap:SubsequentEventMember2026-04-29\n\n[Table of contents](#i6bc77efb1608460996703cf654719a76_7)\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 10-Q\n\n(Mark One)\n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from __________ to __________\n\nCommission File Number 001-38547\n\nAUTOLUS THERAPEUTICS PLC\n\n(Exact name of registrant as specified in its charter)\n\nEngland and Wales\n\nNot applicable\n\n(State or other jurisdiction of incorporation or organization)\n\n(I.R.S. Employer Identification No.)\n\nThe Mediaworks\n\n191 Wood Lane\n\nLondonW12 7FPUnited Kingdom\n\n(Address of principal executive offices)\n\n(44) 20\n3829 6230\n\n(Registrant's telephone number, including area code)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nAmerican Depositary Shares, each representing one ordinary share, par value $0.000042 per share\nAUTLThe Nasdaq Global Select Market\n\nOrdinary shares, nominal value $0.000042 per share**\nThe Nasdaq Stock Market LLC*\n\n*\n\nNot for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\n\nYes ☒ No ☐\n\n1\n\n[Table of contents](#i6bc77efb1608460996703cf654719a76_7)\n\nIndicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “an emerging growth company” in Rule 12b-2 of the Exchange Act:\n\nLarge accelerated filer☐Accelerated filer☐\n\nNon-accelerated filer☒Smaller reporting company\n☒\n\nEmerging growth company☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.\n\nYes ☐ No ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒\n\nAs of May 13, 2026, the registrant had 266,155,786 ordinary shares (including shares in form of American Depositary Shares (“ADSs”)), par value $0.000042 per share, outstanding.\n\n2\n\n[Table of contents](#i6bc77efb1608460996703cf654719a76_7)\n\nEXPLANATORY NOTE\n\nAutolus Therapeutics plc (the “Company”) qualifies as a “Foreign Private Issuer,” as defined in Rule 3b-4 under the Securities Exchange Act of 1934 (the “Exchange Act”) and is exempt from filing quarterly reports on Form 10-Q by virtue of Rules 13a-13 and 15d-13 under the Exchange Act. The Company has voluntarily elected to file this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Accordingly, as a foreign private issuer, the Company remains exempt from the U.S. federal proxy rules pursuant to Section 14 of the Exchange Act and Regulations 14A and 14C thereunder, Regulation FD, and its officers, directors, and principal shareholders are not subject to the short-swing profit disclosure and recovery provisions contained in Section 16 of the Exchange Act.\n\nTABLE OF CONTENTS\n\n[Part I – Financial Information](#i6bc77efb1608460996703cf654719a76_16)\n\n[6](#i6bc77efb1608460996703cf654719a76_16)\n\n[Item 1. Financial](#i6bc77efb1608460996703cf654719a76_19)[S](#i6bc77efb1608460996703cf654719a76_19)[tatements](#i6bc77efb1608460996703cf654719a76_19)[(](#i6bc77efb1608460996703cf654719a76_19)[Unaudited)](#i6bc77efb1608460996703cf654719a76_19)\n\n[6](#i6bc77efb1608460996703cf654719a76_19)\n\n[Condensed Consolidated Balance Sheets as of](#i6bc77efb1608460996703cf654719a76_22)[March 31, 2026](#i6bc77efb1608460996703cf654719a76_22)[and December 31, 202](#i6bc77efb1608460996703cf654719a76_22)5\n\n[6](#i6bc77efb1608460996703cf654719a76_22)\n\n[Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three](#i6bc77efb1608460996703cf654719a76_25)[Months Ended](#i6bc77efb1608460996703cf654719a76_25)[March 31](#i6bc77efb1608460996703cf654719a76_25)[, 202](#i6bc77efb1608460996703cf654719a76_25)[6](#i6bc77efb1608460996703cf654719a76_25)[and 202](#i6bc77efb1608460996703cf654719a76_25)[5](#i6bc77efb1608460996703cf654719a76_25)\n\n[7](#i6bc77efb1608460996703cf654719a76_25)\n\n[Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Three](#i6bc77efb1608460996703cf654719a76_31)[Months Ended](#i6bc77efb1608460996703cf654719a76_31)[Ma](#i6bc77efb1608460996703cf654719a76_31)[r](#i6bc77efb1608460996703cf654719a76_31)[c](#i6bc77efb1608460996703cf654719a76_31)[h 31](#i6bc77efb1608460996703cf654719a76_31)[, 202](#i6bc77efb1608460996703cf654719a76_31)[6](#i6bc77efb1608460996703cf654719a76_31)[and 202](#i6bc77efb1608460996703cf654719a76_31)[5](#i6bc77efb1608460996703cf654719a76_31)\n\n[8](#i6bc77efb1608460996703cf654719a76_31)\n\n[Condensed Consolidated Statements of Cash Flows for the](#i6bc77efb1608460996703cf654719a76_34)[Three](#i6bc77efb1608460996703cf654719a76_34)[Months Ended](#i6bc77efb1608460996703cf654719a76_34)March 31, 2026[and 202](#i6bc77efb1608460996703cf654719a76_34)[5](#i6bc77efb1608460996703cf654719a76_34)\n\n[9](#i6bc77efb1608460996703cf654719a76_34)\n\n[Notes to the](#i6bc77efb1608460996703cf654719a76_37)[Condensed Consolidated Interim Financial Statements](#i6bc77efb1608460996703cf654719a76_37)\n\n[11](#i6bc77efb1608460996703cf654719a76_37)\n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i6bc77efb1608460996703cf654719a76_121)\n\n[30](#i6bc77efb1608460996703cf654719a76_121)\n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#i6bc77efb1608460996703cf654719a76_151)\n\n[40](#i6bc77efb1608460996703cf654719a76_151)\n\n[Item 4. Controls and Procedures](#i6bc77efb1608460996703cf654719a76_157)\n\n[40](#i6bc77efb1608460996703cf654719a76_157)\n\n[Part II – Other Information](#i6bc77efb1608460996703cf654719a76_160)\n\n[40](#i6bc77efb1608460996703cf654719a76_160)\n\n[Item 1. Legal Proceedings](#i6bc77efb1608460996703cf654719a76_163)\n\n[40](#i6bc77efb1608460996703cf654719a76_163)\n\n[Item 1A. Risk Factors](#i6bc77efb1608460996703cf654719a76_166)\n\n[40](#i6bc77efb1608460996703cf654719a76_166)\n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#i6bc77efb1608460996703cf654719a76_172)\n\n[41](#i6bc77efb1608460996703cf654719a76_172)\n\n[Item 3. Defaults Upon Senior Securities](#i6bc77efb1608460996703cf654719a76_175)\n\n[41](#i6bc77efb1608460996703cf654719a76_175)\n\n[Item 4. Mine Safety Disclosures](#i6bc77efb1608460996703cf654719a76_178)\n\n[41](#i6bc77efb1608460996703cf654719a76_178)\n\n[Item 5. Other Information](#i6bc77efb1608460996703cf654719a76_181)\n\n[41](#i6bc77efb1608460996703cf654719a76_181)\n\n[Item 6. Exhibits](#i6bc77efb1608460996703cf654719a76_187)\n\n[41](#i6bc77efb1608460996703cf654719a76_187)\n\n[Signatures](#i6bc77efb1608460996703cf654719a76_190)\n\n[42](#i6bc77efb1608460996703cf654719a76_190)\n\nGENERAL INFORMATION\n\nUnless context otherwise requires, all references in this Quarterly Report on Form 10-Q to “Autolus,” the “Group,” the “company,” “we,” “us” and “our” refer to Autolus Therapeutics plc and its consolidated subsidiaries, except where the context otherwise requires.\n\nAutolus, AUCATZYL® and our other trademarks or service marks appearing in this Quarterly Report on Form 10-Q are our property. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Products or service names of other companies mentioned in this Quarterly Report on Form 10-Q may be trademarks, trade names or service marks of their respective owners.\n\n3\n\n[Table of contents](#i6bc77efb1608460996703cf654719a76_7)\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development costs, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “positioned,” “potential,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.\n\nThe forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:\n\n•the therapeutic potential and expected clinical benefits of AUCATZYL/obe-cel (obecabtagene autoleucel) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (“r/r B-ALL”);\n\n•our ability to generate revenues from AUCATZYL, which is dependent upon maintaining significant market acceptance among physicians, patients and healthcare payors;\n\n•our ability to maintain regulatory approval of AUCATZYL in the US, European Union (“EU”) and United Kingdom (“U.K.”), to obtain and maintain regulatory approval for obe-cel for adult r/r B-ALL in additional territories and the timing thereof, and to obtain and maintain regulatory approval of our other product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;\n\n•our expectations regarding the commercialization and marketing of AUCATZYL for adult r/r B-ALL, including expanding into additional territories and the related timing of reaching patients in such territories;\n\n•the development of our commercial product and product candidates, including statements regarding the initiation, timing, progress and the results of clinical studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;\n\n•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;\n\n•our commercialization, marketing and manufacturing capabilities and strategy for AUCATZYL, including our ability to successfully recruit and retain sales and marketing personnel and to successfully build the market for AUCATZYL;\n\n•our expectations about the willingness of healthcare providers to recommend AUCATZYL to people with adult r/r B-ALL;\n\n•the impacts of public health crises and their effects on our operations and business, including interruption of key clinical trial activities, such as clinical trial site monitoring, access to capital, and potential disruption in the operations and business of third-party manufacturers, clinical sites, contract research organizations (“CROs”), other service providers and collaborators with whom we conduct business;\n\n•our expectations regarding our ability to obtain and maintain intellectual property protection and our ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements;\n\n•our plans to research, develop, manufacture and commercialize our product candidates;\n\n•the potential benefits of our commercial product and product candidates;\n\n•the timing or likelihood of regulatory filings and approvals for our product candidates, along with regulatory developments in the US, EU, U.K. and other foreign countries;\n\n•the size and growth potential of the markets for our commercial product and product candidates, if approved, and the rate and degree of market acceptance of our commercial product and product candidates, including reimbursement that may be received from payors;\n\n•our need for and ability to obtain additional funding, on favorable terms or at all;\n\n•our plans to collaborate, or statements regarding our current collaborations with BioNTech SE (“BioNTech”) and others;\n\n•our license and option agreement with BioNTech (the “BioNTech License and Option Agreement”), including our potential to receive milestone payments and royalties under the agreement;\n\n•our ability to attract collaborators with development, regulatory and commercialization expertise;\n\n•our ability to identify, recruit and retain qualified employees and key personnel;\n\n•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;\n\n•the scalability and commercial viability of our manufacturing methods and processes;\n\n•the success of competing therapies that are or may become available;\n\n•whether we are classified as a Passive Foreign Investment Company (“PFIC”), for current and future periods;\n\n4\n\n[Table of contents](#i6bc77efb1608460996703cf654719a76_7)\n\n•additional costs and expenses related to our decision to voluntarily comply with certain U.S. domestic issuer reporting obligations before we are required to do so; and\n\n•any other factors which may impact our financial results or future trading prices of our ADSs, and the impact of securities analysts’ reports on these prices.\n\nAlthough we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, and involve known and unknown risks, uncertainties and other factors including, without limitation, risks, uncertainties and assumptions regarding the impact of macroeconomic events, including inflation, changes in interest rates, tariffs, changes in trade policies, political changes, general market conditions and the impacts of the war in Ukraine, conflicts in the Middle East and Europe, and global geopolitical tensions, on our business, operations, strategy, goals and anticipated timelines, our ongoing and planned preclinical activities, our ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, our timelines for regulatory submissions and our financial position that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You are urged to carefully review the disclosures we make concerning these risks and other factors that may affect our business and operating results in this Quarterly Report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Except as required by law, we do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances.\n\n5\n\n[Table of contents](#i6bc77efb1608460996703cf654719a76_7)\n\nPART I - FINANCIAL INFORMATION"}